Graham J, McBride D, Stull D, Halliday A, Alexopoulos ST, Balp M, Griffiths M, Agirrezabal I, Brennan A. Cost-utility of omalizumab compared with standard of care for the treatment of chronic spontaneous urticaria (CSU). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Partha G, Gupta S, Bhattacharyya S, Halliday A, McBride D, Graham J, Balp MM, Marsland A. Adapting literature-based remission rates for chronic spontaneous/idiopathic urticaria to the needs of a health economic model: a Kaplan-Meier approach. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Graham J, Luthra R, Earnshaw S, Borker R. Cost-effectiveness of afatinib vs. erlotinib in the 1st-line treatment of metastatic NSCLC patients with EGFR exon 19 deletion mutations. Poster presented at the 16th World Conference on Lung Cancer; September 6, 2015. Denver, CO.
Mauskopf JA, Graham J, Fay-Azhar M, Kinter E. Budget impact of adding peginterferon beta-1a to the formulary for the treatment of relapsing forms of multiple sclerosis. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Benson C, Chirila C, Graham J, Radder C, Zheng Q, Muser E, Woodruff K. Health resource use and cost analysis of schizophrenia patients participating in a randomized, multicenter, double-blind, relapse prevention study of paliperidone palmitate 3-month formulation. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Talbird SE, Graham JB, Mauskopf JA, Masseria C, Krishnarajah G. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases. J Manag Care Pharm. 2015 Jan;21(1):88-99.